Anzeige
Mehr »
Dienstag, 03.02.2026 - Börsentäglich über 12.000 News
Der Countdown läuft: Warum diese Aktie 2026 spannend werden könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
03.02.26 | 10:39
194,64 Euro
-0,54 % -1,06
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
194,94195,3210:40
194,82195,4010:40

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoJ&J 4Q Results18
MoCHMP grants positive opinion for J&J's Akeega use8
MoUS judge dismisses fraud lawsuit tied to Johnson & Johnson talc bankruptcy strategy4
SaInsider trades: JNJ, Intel, IBM among notable names50
SaNotable analyst calls this week: J&J, Applied Materials and Pinterest among top picks7
FrJ&J wins EU backing for Akeega label expansion3
FrJohnson & Johnson Says AKEEGA Wins CHMP Backing For Metastatic Prostate Cancer With BRCA1/2 Mutation376NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an indication...
► Artikel lesen
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
FrJ&J gets dismissal of fraud claims tied to talc bankruptcy5
FrUS judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy8
DoScotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results7
MiJohnson & Johnson: Neue Produkte treiben die Fantasie12
MiJohnson & Johnson upgraded at Morgan Stanley on growth outlook13
MiJohnson & Johnson MedTech hits $100M medtech product donation milestone3
MiJohnson & Johnson stock rating upgraded by Morgan Stanley on growth outlook15
MiMorgan Stanley stuft Johnson & Johnson wegen Wachstumsaussichten hoch26
MiJ&J Secures FDA Approval For DARZALEX FASPRO Combo In Newly Diagnosed Multiple Myeloma379NEW BRUNSWICK (dpa-AFX) - Drug major Johnson & Johnson (JNJ) announced Tuesday that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) -based quadruplet regimen has received the U.S. Food...
► Artikel lesen
27.01.Johnson & Johnson: DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible451Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of...
► Artikel lesen
27.01.J&J's Darzalex Faspro gains another multiple myeloma indication5
27.01.Johnson & Johnson price target raised to $220 from $190 at Freedom Capital7
27.01.J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units6
Weiter >>
777 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,2,9